Laurus Labs Limited (NSE:LAURUSLABS)
India · Delayed Price · Currency is INR | Market Cap | 468.92B |
| Revenue (ttm) | 59.29B |
| Net Income (ttm) | 5.09B |
| Shares Out | 539.82M |
| EPS (ttm) | 9.45 |
| PE Ratio | 91.95 |
| Forward PE | 65.61 |
| Dividend | 1.60 (0.18%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 1,156,775 |
| Average Volume | 2,168,748 |
| Open | 868.65 |
| Previous Close | 868.65 |
| Day's Range | 856.20 - 876.50 |
| 52-Week Range | 427.05 - 922.50 |
| Beta | 0.36 |
| RSI | 57.87 |
| Earnings Date | Jul 25, 2025 |
About Laurus Labs
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition,... [Read more]
Financial Performance
In 2024, Laurus Labs's revenue was 55.54 billion, an increase of 10.18% compared to the previous year's 50.41 billion. Earnings were 3.58 billion, an increase of 123.18%.
Financial StatementsNews
Laurus Labs to dissolve CDMO arm Laurus Synthetics as part of rejig
Hyderabad: In a restructuring exercise, Laurus Labs is demerging Unit-1, which is the API manufacturing component of its contract development and manu.
Why are Laurus Labs shares up over 2% today? Explained
Shares of Laurus Labs Ltd surged over 2% to ₹856.25 in early trade on Monday, making it one of the top gainers on the NSE. The sharp upmove comes on the back of a stellar Q1 performance, a major land ...
Stocks to watch on brokerages, July 28: Mphasis, Cipla, Kotak Bank, Laurus Labs, IDFC First Bank, Bank of Baorda, SBI Cards, and more in focus
A full of brokerage actions is likely to impact several stocks on July 28, as global and domestic firms issued fresh views following earnings and business developments. Key names on the radar include ...
Antique maintains hold on Laurus Labs, raises target to Rs 700 as CDMO momentum persists but visibility stays limited
Antique Stock Broking has maintained a Hold rating on Laurus Labs, while raising its target price to ₹700 from ₹520, reflecting a more balanced view on the company’s growth outlook despite ongoing exe...
Motilal Oswal maintains buy on Laurus Labs, raises target to Rs 970 on strong CDMO-led earnings momentum
Motilal Oswal Financial Services (MOSL) has maintained a Buy rating on Laurus Labs, raising its target price to ₹970 from ₹860. The revised target suggests continued confidence in the company’s growth...
Kotak Institutional Equities maintains sell on Laurus Labs, raises target to Rs 555 as earnings recovery seen priced in
Kotak Institutional Equities has reiterated a Sell rating on Laurus Labs, while raising the target price to ₹555, implying a sharp downside of approximately 34% from the current market price of ₹839.9...
Jefferies maintains underperform on Laurus Labs, raises target to Rs 590 as margin concerns persist despite Q1 beat
Jefferies has maintained an Underperform rating on Laurus Labs, while raising its target price to ₹590 — implying a downside of approximately 29.8% from the current market price of ₹839.90. The compan...
Goldman Sachs maintains sell on Laurus Labs, raises target to Rs 675 citing limited visibility despite margin optimism
Goldman Sachs has maintained a Sell rating on Laurus Labs, while raising the target price to ₹675. The revised target implies a downside of approximately 20% from the current market price of ₹839.90. ...
Laurus Labs posts sharp rise in net profit for Q1FY26
Hyderabad: Pharma player Laurus Labs has posted a significant 1,154% rise in net profit for the quarter ended June 30, 2025, at Rs 163 crore compared .
Stocks to watch on Q1 results today, July 25: Bajaj Finserv, Bank of Baroda, Cipla, SAIL, SBICard, Shriram Finance, and 40 others in focus
Indian equities are set for an action-packed session on Thursday, July 25, as several major and mid-sized companies will announce their financial results for the first quarter of FY26. Among the key n...
Top stocks at 52-week highs today, July 15: RBL Bank, Force Motors, Laurus Labs, CSB Bank and more
Indian markets began the week with strong gains on Monday, July 15, as the BSE Sensex rallied 317 points to close at 82,570.91, while the NSE Nifty 50 advanced 113.5 points to end at 25,195.80. The bu...
Stocks hitting 52-week highs today, June 16: Bharat Electronics, Laurus Labs, Max Healthcare, JK Cement and more
Indian equity markets closed on a positive note on June 16, 2025, as benchmark indices posted strong gains across the board. The BSE Sensex surged 677.55 points (0.84%) to close at 81,796.15, while th...
Laurus Labs shares in focus as pharma exports for May 2025 double YoY
Shares of Laurus Labs were trading up by 0.91% at ₹672.65 on June 16 after India’s pharma export data for May 2025 revealed a strong performance by the company. According to official trade data, Lauru...
Laurus Labs Q4 Results: Revenue up 19.4% to Rs 1,720 crore, Net profit surges 210% YoY
Laurus Labs Ltd. reported strong financial performance for the quarter ended March 31, 2025 (Q4FY25), with a remarkable 211% year-on-year (YoY) increase in net profit, driven by higher revenues and a ...
Stocks hitting 52-week highs today, April 23: Laurus Labs, UPL, Bharti Hexacom, HDFC Bank and more
The Indian equity markets ended Wednesday, April 23, 2025, on a bullish note with major benchmark indices witnessing a sharp rally. The Nifty 50 surged past the 24,300 mark, closing at 24,328.95, up 1...
Stocks hitting 52-week highs today, April 22: HDFC Bank, Laurus Labs, Bharti Hexacom, Eicher Motors and more
The Indian stock market continued its upward trajectory for the sixth consecutive trading session on April 22, 2025. Both benchmark indices ended in green, with the BSE Sensex rising by 187.09 points ...
Laurus Labs receives EIR from USFDA for API manufacturing facility (Unit-4) at Atchutapuram
Laurus Labs has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its API manufacturing facility, Unit–4, located at Atch...
Stocks hitting 52-week high today, February 5: UPL, Laurus Labs, Bajaj Finance, JK Cement and more
On February 5, 2025, the Indian equity markets experienced a decline, with both the Nifty 50 and Sensex indices closing lower. Despite the market slowdown, several stocks managed to hit their 52-week ...
Laurus Labs stock jumps 5% after US grants emergency humanitarian waiver for HIV treatment
Laurus Labs’ stock price surged by 5% following the United States’ approval of an “emergency humanitarian waiver,” allowing continued access to HIV treatment across 55 countries. This waiver, crucial ...
Laurus Labs shares tumble amid concerns over US foreign aid pause impacting AIDS relief funding.
Hyderabad: The shares of Hyderabad-based pharma player Laurus Labs crashed 15% before recovering to close 11% down on the bourses on Monday.
Laurus Labs Ltd (BOM:540222) Q3 2025 Earnings Call Highlights: Strong CDMO Growth Amid ARV ...
Laurus Labs Ltd (BOM:540222) Q3 2025 Earnings Call Highlights: Strong CDMO Growth Amid ARV Challenges
Q3 2025 Laurus Labs Ltd Earnings Call Transcript
Q3 2025 Laurus Labs Ltd Earnings Call Transcript
Laurus Labs clarifies on reports of impact of Antiretroviral business, says no significant impact
Laurus Labs Limited has addressed recent media reports regarding the temporary freeze of funding under the US President’s Emergency Plan for AIDS Relief (PEPFAR) for 90 days. The company has clarified...
Laurus Labs shares fall 10% as ARV funding concerns weigh heavily
Shares of Laurus Labs fell sharply by 10% on January 27, 2025, closing at ₹542.40, amid negative sentiment triggered by reports of a potential halt in U.S. foreign aid funding for AIDS relief programs...
Laurus Labs Q3 FY25 Financial Results: Revenue up 18.4% YoY to Rs 1415.05 crore, Net Profit up 297% YoY
Laurus Labs Limited has released its consolidated unaudited financial results for the quarter ended December 31, 2024. The results highlight steady performance across revenue and profitability metrics...